DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+13.79%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$2.38B
AUM Growth
+$2.38B
(-6.9%)
Cap. Flow
-$217M
Cap. Flow
% of AUM
-9.13%
Top 10 Holdings %
Top 10 Hldgs %
36.37%
Holding
147
New
12
Increased
26
Reduced
28
Closed
38
Top Buys
Top Sells
| 1 |
BLUE
bluebird bio
BLUE
|
$41.3M |
| 2 |
NXTM
NxStage Medical Inc.
NXTM
|
$37.9M |
| 3 |
ELGX
Endologix Inc
ELGX
|
$28.8M |
| 4 |
Pacira BioSciences
PCRX
|
$25.5M |
| 5 |
GSK
GSK
|
$24.5M |
Sector Composition
| 1 | Healthcare | 70.92% |
| 2 | Financials | 4.5% |
| 3 | Technology | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Gilead Sciences
GILD
$140B
| – | – |
0
| – | – |
|
127
Edwards Lifesciences
EW
$47.7B
| – | – |
-97,119
| Closed | -$13.8M |
|
128
Penumbra
PEN
$10.5B
| – | – |
-100,000
| Closed | -$4.01M |
|
129
Bausch Health
BHC
$2.72B
| – | – |
-1,575
| Closed | -$281K |
|
130
Biogen
BIIB
$20.8B
| – | – |
-5,500
| Closed | -$1.61M |
|
131
Brookdale Senior Living
BKD
$1.81B
| – | – |
-557,000
| Closed | -$12.8M |
|
|
BLUE
132
DELISTED
bluebird bio
BLUE
| – | – |
-483,000
| Closed | -$41.3M |
|
133
Cardinal Health
CAH
$36B
| – | – |
-8,000
| Closed | -$615K |
|
134
Esperion Therapeutics
ESPR
$490M
| – | – |
-32,970
| Closed | -$778K |
|